Bulletin from the annual general meeting of Alzinova AB (publ)
The following resolutions were passed at the annual general meeting (the “AGM”) of Alzinova AB (publ) (“the Company”) on 18 May 2021. Due to the covid-19 pandemic, the Company’s annual general meeting was carried out through advance voting (postal voting) only.
Adoption of income statement and balance sheet and discharge from liability
The AGM resolved to adopt the income statement for the financial year 2020 as well as the balance sheet as of 31 December 2020. The members of the board of directors and the managing director were discharged from liability for the financial year 2020.
Allocation of profit or loss
The AGM resolved, in accordance with the Board of Directors’ proposal, that no dividend shall be paid for 2020 and that the results of the Company shall be carried forward.
Board of Directors and auditor
The AGM resolved, in accordance with the nomination committee’s proposal, on re-election of Björn Larsson, Clas Malmeström, Carol Routledge, Anders Waas, Pernilla Sandwall, Lena Degling Wikingsson and Per-Göran Gillberg, and election of Anders Blom as board members. Furthermore, the deputy board members Anders Sandberg and Jesper Dahlberg were re-elected. Björn Larsson was re-elected as the chairman of the Board of Directors. The AGM re-elected the audit firm Ernst & Young.
The AGM further resolved on remuneration to the Board of Directors in accordance with the nomination committee’s proposal. The AGM furthermore resolved in accordance with the nomination committee’s proposal, that remuneration to the auditor shall be paid in accordance with approved statement of costs.
Authorisation to issue new shares, warrants or convertibles
The AGM resolved, in accordance with the Board of Directors’ proposal, to authorise the Board of Directors to, at one or several occasions and for the period up until the next annual general meeting, resolve to increase the Company’s share capital by issuing new shares, warrants or convertibles. Such issue resolution may be carried out with or without deviation from the shareholders’ preferential rights and with or without provisions for contribution in kind, set-off or other conditions.
The total number of shares that may be issued, or in the event of an issue of convertibles or warrants,
any additional shares after conversion or exercise, pursuant to the authorisation shall, for resolutions taken without deviation from the shareholders' preferential rights, not be limited in any other way than by the limits for the share capital and number of shares, as set forth from time to time in the registered articles of association. For resolutions made with deviation from shareholders' preferential rights, the total number of shares that may be issued, or in the event of an issue of convertibles or warrants, any additional shares after conversion or exercise, pursuant to the authorisation shall be limited to a dilution for existing shareholders of ten (10) percent.
Furthermore, a new issue resolved pursuant to the authorization that takes place without preferential rights for the shareholders shall be made to broaden and strengthen the ownership with strategic shareholders, procuring or facilitating the procurement of working capital, increasing the liquidity of the share, making acquisitions, or procuring or facilitating the procurement of capital for acquisitions. At first hand, it should be directed to new shareholders with expertise in the field and with a strong financial position, but it may also be that the Board, due to time and cost reasons, has come to the conclusion that a directed new issue is more suitable than a rights issue.
"We are very happy to welcome Anders Blom as new board member of Alzinova AB. With his experience, he will contribute valuable skills to the board as the Company now makes the transition into a new phase," says Björn Larsson, Chairman of the Board.
For more information, please contact:
Kristina Torfgård, CEO
Telephone: +46 70 846 79 75
About Alzinova AB
Alzinova AB is a Swedish biopharma company specializing in the treatment of Alzheimer’s disease targeting neurotoxic amyloid-β oligomers. The lead candidate, ALZ-101, is in late preclinical development as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that target the toxic amyloid-β oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201, in early preclinical development, was generated with the AβCC peptide™ technology and the ambition is to expand the pipeline further. The company’s Certified Advisor on Nasdaq First North Growth Market is Corpura firstname.lastname@example.org +46 768-532 822. For more information about Alzinova, please visit: www.alzinova.com